The FDA has approved Genmab’s Epkinly for the treatment of adults with follicular lymphoma that has relapsed or is refractory after two or more lines of systemic therapy.

Epkinly’s approval was based on results from the Phase I/II EPCORE trial in patients with relapsed or refractory follicular lymphoma who had previously completed two or more lines of systemic therapy.